Breaking News, Collaborations & Alliances

Gilead, LEO Pharma Partner to Accelerate Development of Oral STAT6 Program

Strengthens Gilead’s inflammation research portfolio with the addition of LEO Pharma’s preclinical Oral STAT6 program, including targeted protein degraders.

Author Image

By: Charlie Sternberg

Associate Editor

Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases. STAT6 is the transcription factor essential for signaling of IL-4 and IL-13 cytokines, which are well-established targets for Th2-mediated inflammatory diseases like atopic dermatitis, asthma, and COPD, among others. Precl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics